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Migraine and tension-type headache in Germany. Prevalence and 
disease severity from the BURDEN 2020 Burden of Disease Study
Abstract
Headache disorders are widespread among women and men in Germany and are primarily associated with restrictions 
on quality of life. The two most common types of headache disorders are migraine and tension-type headache. In order 
to gain valid estimates of the prevalence of these conditions, a cross-sectional telephone-based survey was conducted 
among adults in Germany (N=5,009) between October 2019 and March 2020. The frequency, duration, the characteristics 
and comorbidities associated with headache were measured using the diagnostic criteria defined in the International 
Classification of Headache Disorders. 57.5% of women and 44.4% of men in Germany stated that they had had a headache 
in the last twelve months. 14.8% of women and 6.0% of men meet all of the diagnostic criteria for migraine. Tension-
type headache affects 10.3% of women and 6.5% of men. Migraine and tension-type headache are predominantly found 
among people of working age and steadily decrease with age. Migraine is often accompanied by comorbidities such as 
depressive symptoms and anxiety disorders. People affected by headache disorders tend to receive very little professional 
medical care, with only a minority seeking treatment within a year. These results provide a comprehensive picture of the 
population-related impact of headache disorders and are used in the BURDEN 2020 study to quantify key indicators for 
burden of disease assessment.
  MIGRAINE · TENSION-TYPE HEADACHE · BURDEN OF DISEASE · MEDICATION · COMORBIDITIES
1. Introduction
Headache is widespread and among the recurrent symp-
toms and disorders that many people experience [1]. Already 
in the telephone-based health survey GSTel 2004, conduct-
ed by the Robert Koch Institute (RKI), was reported that 
66.6% of women and 53.0% of men in Germany have had 
a headache in the past twelve months [2]. Furthermore, the 
German Health Interview and Examination Survey for Chil-
dren and Adolescents (KiGGS Wave 2, 2014–2017) found 
that 45.2% of 11- to 17-year-old girls and 28.7% of boys of 
the same age were affected by recurring headache during 
the last three months [3]. 
Several major epidemiological studies of the German 
population have provided estimates of the prevalence of 
tension-type headache and migraine – the two most com-
mon headache disorders. A migraine is characterised by a 
unilateral, pulsating or throbbing pain that patients describe 
as moderate to severe and which is usually aggravated by 
physical activity. Migraine may be accompanied by nausea, 
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vomiting and photo- and phonophobia. If this condition is 
accompanied by additional restrictions to a person’s field 
of vision (flashing or lightning streaks) or language and 
speech disorders, it is referred to as migraine with aura. In 
some cases, one or more limbs may become numb during 
a migraine attack. In contrast, tension-type headache is 
characterised by a bilateral, pressing or tightening (non-pul-
sating) pain that patients describe as mild to moderate and 
which is not aggravated by physical activity. A tension-type 
headache may be accompanied by photo- and phonopho-
bia, but not by both symptoms at the same time [4].
The frequency of headache disorders fluctuates due to 
the different types of sample and survey modes of the 
studies. Migraine frequency has been found to vary from 
between 15.6% and 23.9% among women and between 4.0% 
and 11.1% among men, whereas tension-type headache can 
vary from 14.5% and 31.7% among women and between 
12.0% and 26.9% among men [1, 2, 5, 6]. In most health-
care statistics, the importance of general headache or of 
migraine and tension-type headache is not reported. As the 
majority of people affected by headache usually does not 
seek medical help and is normally unable to work for only a 
short period of time, it is difficult to use claims data or data 
on wage replacement benefits to estimate headache preva-
lence. Therefore, headache disorders are not among the 30 
most common diagnoses made in general practices. Even 
in neurological outpatient practices, which provide profes-
sional care for people with these conditions, migraine (Inter-
national Statistical Classification of Diseases and Related 
Health Problems, 10th Revision, ICD-10: G43) and other 
headache syndromes (ICD-10: G44) only represent 4.4% 
and 3.8% of all treated cases respectively [7, 8]. Accordingly, 
the health insurance provider Barmer Ersatzkasse reports 
that the proportion of their policy holders who are treated 
for headache disorder remains in the single-digit range 
[9, 10]. Headache (ICD-10: R51) and migraine (ICD-10: G43) 
also only account for 1.9% of cases of incapacity to work and 
0.8% of days lost through incapacity to work among the 
insured people [10]. However, the costs associated with these 
conditions are higher once the indirect costs are taken into 
account. The indirect costs can be calculated using survey 
data and are caused by the reduction in performance and 
productivity of people who continue to work despite their 
condition. According to the European Union (EU) Eurolight 
study (2008–2009), indirect costs account for more than 
90% of the total costs that are estimated to be associated 
with headache [11, 12].
The public health relevance of headache disorders is par-
ticularly apparent from the impact on quality of life that 
headache has on the people affected and those around 
them. Many people find that headache disorders severely 
restrict their ability to carry out normal daily activities. In 
addition to reduced performance at work, headache leads 
people to reduce their level of social contact and to avoid 
leisure activities [11, 13]. Even the fear of being affected by 
another headache episode can have a major impact on qual-
ity of life and promote further comorbidites such as depres-
sion, sleep disorders and other pains [13, 14].
 The reduced quality of life due to illness-related restric-
tions is measured in the burden of disease assessment 
by calculating the loss of healthy life-years [15]. According 
to the Global Burden of Disease Study (Info box), in 2017 
in Germany, migraine accounted for 5.1% of all years lived 
with disability (YLD) and ranked second among all 
Info box: 
The burden of disease
The Global Burden of Disease Study undertakes 
comprehensive calculations of the burden associ-
ated with disease throughout the world and, there-
fore, is an important informational system that can 
be used for international comparisons [15]. The 
study adds the figures for premature mortality 
(years of life lost, YLL) and healthy years of life lost 
due to illness (years lived with disability, YLD) to 
obtain a total measure known as DALY (disabili-
ty-adjusted life years). Therefore, instead of simply 
comparing disease frequency, the study compares 
the impact that certain conditions have on popu-
lation health, measured as loss of healthy lifetime. 
Since headache disorders are not a cause of death 
in the sense of the coding requirements defined 
by the World Health Organization (WHO), they 
are not included in YLL calculations. The propor-
tion of the total burden of disease for headache 
disorders, therefore, is lower when expressed in 
DALY than when measured in YLD. However, 
migraine was still ranked ninth among all illnesses 
in 2017, and was responsible for 2.4% of DALY in 
Germany [54].
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social determinants of headache disorders are also exam-
ined as part of a multivariate analysis. This article also anal-
yses the utilisation of outpatient medical services and the 
use of medication by people with headache disorders, 
including the frequency of medication overuse.
2. Methodology
2.1 Data collection
A nationwide cross-sectional telephone survey of headache, 
back and neck pain was conducted in Germany between 
October 2019 and March 2020. The study targeted Ger-
man-speaking residents of Germany aged 18 and older. 
It was developed by the RKI and carried out by USUMA 
GmbH, a market and social research institute. Implemen-
tation and quality assurance were performed based on a 
standardised concept [28]. Potential participants were con-
tacted using a sample of landline and mobile phone num-
bers that had been randomly selected using the ADM 
(Working Group of German Market and Social Research 
Institutes) telephone sampling system [29]. The overall 
sample comprises 60% landline and 40% mobile phone 
numbers [29]. As every telephone number in Germany was 
eligible for the sample used by the study, it is representa-
tive of all households that are reachable by telephone in 
Germany. Landline telephone numbers were selected ran-
domly using the Kish selection grid [28].
The study used a questionnaire that was based on those 
used by the RKI for other telephone-based health monitor-
ing studies [28]. Validated instruments for measuring 
headache, back and neck pain were selected in advance 
and implemented as part of the questionnaire to ensure 
illnesses. Migraine is associated with more severe restric-
tions on quality of life and, therefore, is more important 
than tension-type headache, which accounted for 0.7% of 
YLD and ranked 31st [16]. However, the reliability of the 
results from the Global Burden of Disease Study is limited 
due to difficulties with data availability [17–19]. As such, it 
is very important that headache disorders are integrated 
into national health surveys to improve the data pool avail-
able for calculating the burden of disease [20].
The study ‘BURDEN 2020 – Burden of disease in Ger-
many at the national and regional level’ estimates the YLD 
for several important illnesses, including tension-type 
headache and migraine [21]. The aim of the study is to 
improve the data pool used for calculating the burden of 
disease in Germany and to adapt it to specific informational 
needs. Measuring the prevalence by using the criteria of 
the International Classification of Headache Disorders [4], 
and the operationalisation of severity levels for headache 
disorders according to the definition of the Global Burden 
of Disease Study [22], provides certain challenges. Rele-
vant studies in Germany, were either conducted some time 
ago, cover only specific regions or do not provide all of 
the necessary information [1–3, 5, 6, 23–27]. Therefore, a 
population-based survey of pain disorders was conducted 
as part of the BURDEN 2020 framework in order to collect 
up-to-date data.
This article uses data from the study to provide an over-
view of headache disorders in Germany, and particularly of 
migraine and tension-type headache. It focuses on the fre-
quency of headache disorders and their distribution by age 
and sex. It also outlines the severity of headache disorders 
in terms of their duration, intensity and frequency. The 
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not use pain medication or if their medication was unhelp-
ful. Participants are classified as suffering from migraine 
if they have had at least five attacks in their lifetime (A), 
lasting between four and 72 hours (B), meet at least two 
of four additional characteristics (C) and their headaches 
are accompanied by at least one of two specified accom-
panying symptoms (D). Cases that meet all four character-
istics (A–D) are described as ‘definite migraine’, whereas 
those that meet three characteristics are categorised as 
‘probable migraine’.
Participants are classified as suffering from tension-type 
headache if they have had at least ten attacks in their life-
time (A), lasting between 30 minutes and seven days (B), 
meet at least two out of four additional characteristics (C), 
and their headache is accompanied by the two specified 
accompanying symptoms (D). Cases that meet all four 
characteristics (A–D) are described as ‘definite tension-type 
headache’, whereas those that meet three characteristics 
are categorised as ‘probable tension-type headache’.
Migraine can be further categorised according to it´s clin-
ical symptoms as migraine with or without aura (Table 1). 
Cases of (definite or probable) migraine that also includes 
restrictions on a person’s field of vision, weakness in their 
limbs or speech disorders are classified as migraine with 
aura (Table 1). Furthermore, (definite) migraine and (defi-
nite) tension-type headache can be subdivided into epi-
sodic headache (if they occur on less than fifteen days per 
month) and chronic headache (if they occur on fifteen or 
more days per month).
All participants who had had one or more headache in 
the past twelve months were given the opportunity to 
describe their headache. They were asked the following ques-
comparable results and to enable the identification of 
temporal trends [1, 30–34]. The study collected detailed 
information on the characteristics associated with individ-
ual pain disorders. Data were also gathered on general 
health and life satisfaction. Information on the medication 
use of people with headaches was also collected. On aver-
age, the interviews lasted 23 minutes. The questionnaire 
is avail able on request. The response rate, which was cal-
culated using criteria drawn up by the AAPOR (American 
Association for Public Opinion Research), was 24.0% [35].
2.2 Measuring migraine and tension-type headache
For headache disorders, an instrument for migraine imple-
mented in the RKI’s 2004 GSTel health survey has been 
further developed [5, 32]. The aim was to enable migraine 
and tension-type headache to be measured in line with the 
diagnostic criteria set out in the International Classification 
of Headache Disorders (ICHD – 3rd edition) [4], which is 
also used by the Global Burden of Disease Study [22]. The 
ICHD criteria can be summarised as four key indicators: 
(i) frequency, (ii) duration, and (iii) the characteristics of 
and (iv) comorbidities associated with headache attacks.
Table 1 provides an overview of how the indicators were 
built to identify people affected by migraine or tension-type 
headache in line with the ICHD criteria. In order to mea-
sure headache intensity, respondents were asked to classify 
their headache as mild, moderate or severe. Additionally, 
the mean frequency of headache attacks per month and 
the duration of attacks were also recorded. In accordance 
with the ICHD criteria, respondents were asked to estimate 
how long they would expect a headache to last if they did 
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tension-type headache. Finally, a probable migraine was 
given priority over a probable tension-type headache. 
The following analysis focuses on (Figure 1): 
  People with headache in the last twelve months.
  People with (definite) migraine.
  People with (definite) tension-type headache.
In the following, the terms ‘migraine’ and ‘tension-type 
headache’ are used to refer to definite migraine and defi-
nite tension-type headache.
Headache due to medication overuse is a comparatively 
rare phenomenon with a prevalence of between 1% and 2% 
among adults [36, 37]. It can occur when a person takes a 
tion: ‘Do you always have the same type of headache or do 
you have different types of headache?’ People who had dif-
ferent types of headache were asked two times to describe 
the frequency, duration, and characteristics, as well as the 
accompanying  symptoms of their headaches. Each headache 
was then categorised either as a migraine or a tension-type 
headache in a way that the described headache could not 
meet all of the criteria for migraine and tension-type 
headache at the same time. Definite headache types were 
given priority over probable headache, which means that 
cases that met the characteristics for probable tension-type 
headache and definite migraine were classified as a migraine. 
Cases that met the characteristics for probable migraine 
and for definite tension-type headache were classified as a 
Table 1 
Indicators to measure migraine and 
tension-type headache
Source: Own table
Migraine (without aura) Tension-type headache
A.  Frequency At least five episodes over a person’s lifetime At least ten episodes of headache occurring over a 
person’s lifetime
B.  Duration of the 
attacks
4–72 hours (when untreated or unsuccessfully treated) Lasting from 30 minutes to seven days  
(when untreated or unsuccessfully treated)
C.  Characteristics At least two of the following four characteristics:
1.  unilateral location
2.  Pulsating quality
3.  Moderate or severe pain intensity
4.  Aggravation by or causing avoidance of routine 
physical activity (e.g. walking or climbing stairs) 
At least two of the following four characteristics:
1.  Bilateral location
2.  Pressing ot tightening (non-pulsating) quality
3.  Mild or moderate intensity
4.  Not aggravated by routine physical activity such as 
walking or climbing stairs
D. Comorbidities During headache at least one of the following:
1.  Nausea and/or vomiting
2.  Photophobia or phonophobia
Both criteria are met:
1.  No nausea or vomiting
2.  No more than one of photophobia or phonophobia
Additional indicator Migraine (with aura)
1.  Criteria for Migraine (without Aura) are fulfilled
2.  In addition, the person fulfills at least one of the 
following criteria: 
 a.  Experiencing flimmer or flash in front of eyes, 
for at least 5 minutes
     b.  Weakness, paralysis or numbness of limbs,  
 or impaired speech
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In addition to information on the frequency of certain 
types of headache in the population, further information 
was collected to better describe the respondents' headache 
disorders. This includes information about other diseases 
and conditions that the respondents reported. Studies have 
identified relevant associations between pain and mental 
disorders [13]. Depression and anxiety disorders are par-
ticularly relevant in this context. Therefore, data on depres-
sive symptoms and anxiety disorders were recorded and 
this was done by collecting self-reported information on 
the four items set out in the Patient Health Questionnaire 
(PHQ-4). The symptoms reported were then assessed 
according to the frequency of their occurrence over the past 
two weeks. The criteria for depression and generalised anx-
iety disorder defined by the American Psychiatric Associa-
tion’s Diagnostic and Statistical Manual of Mental Disor-
ders (DSM-V) include two items for each of the diseases. 
A scale of zero to six was used in both cases; exceeding the 
threshold by at least three points was regarded as an 
large amount of medication to treat acute pain, including 
pain caused by migraine and tension-type headache. In 
order to determine if participants are affected by this con-
dition, respondents were asked to list up to five medications 
that they take as a prophylaxis or to treat acute headache 
and other pain conditions. The interviewers recorded the 
responses using an extensive list of medication (brand or 
trade names) that are used to treat headache and other pain 
disorders. Participants were also allowed to describe the 
active ingredients that their medication contained. Addi-
tional space was available to provide details about non-
listed medications. The participants were also asked how 
long and how often they took the medication. The ICHD 
was used to categorise medication overuse among people 
who reported headaches on at least fifteen days a month 
and who took common pain relievers (e.g. paracetamol, 
ibuprofen, acetylsalicylic acid or mixed analgetics) on at 
least fifteen days a month or triptans, ergotamine or opioids 
on at least ten days a month. In both cases, the participants 
had to have taken the medication for more than three 
months.
Figure 1 
Schematic representation of headache based 
on the Global Burden of Disease study 
Source: Own diagram
Headache
(in the last twelve months)
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In order to ensure that the sample was representative for 
the population in Germany, it was adjusted for an individu-
al’s probability of selection (design weighting) and for pop-
ulation structure (adjustment weighting). Design weighting 
was used to correct for the sample, where a method deter-
mining the selection probability in a telephone-based sam-
ple consisting of both landline and mobile phone numbers 
(dual frame design) was applied [29]. Adjustment weighting 
was carried out iteratively by sex, age, education and region 
to ensure that the distribution of these characteristics is sim-
ilar to that found in the resident population in Germany aged 
18 and older. Data from the Federal Statistical Office (pop-
ulation as of 31 December 2018) and the microcensus from 
2017 served as a basis for this comparison [41, 42]. 
Statistical associations between various characteristics 
were also tested. The Pearson χ2 test for survey samples 
was used for nominal data [43]. With regard to purely 
metric values, differences in mean values between groups 
were determined using the t-test [44]. Multinomial logistic 
regression was also used to identify the social determinants 
of headache disorders [45–47]. The target variables were 
probable and definite migraine, tension-type headache and 
the remaining group of all other headache types. Partici-
pants with both migraine and tension-type headache 
were assigned to the migraine group. Participants without 
headaches served as the comparison group. A statistically 
significant difference between groups is assumed when the 
corresponding p-value is smaller than 0.05. All analyses were 
carried out using STATA (StataCorp LLC, Texas, US) version 
15.1. All of the results presented in this article, including 
indication of depressive symptoms or an anxiety disorder 
[38]. In addition, data on back and neck pain were collect-
ed using self-reported information on twelve-month preva-
lence, since these conditions can also be associated with 
migraine and tension-type headache [13]. A particular focus 
was placed on respondents who reported severe to very 
severe back or neck pain.
Furthermore, data were also collected on sociodemo-
graphic factors such as education, household composition 
and employment status. A distinction was made between 
unemployed people, people looking for work and employed 
or retired people. The 2011 International Standard Classi-
fication of Education (ISCED), which was drawn up by the 
United Nations Educational, Scientific and Cultural Organ-
ization (UNESCO), allows for international comparisons 
of educational levels and for classifying the highest achieved 
level of education in three groups (low, middle, high) 
according to EU standards [39]. Information on whether 
the respondent lived with a partner was also taken into 
account. Perceived levels of social support in a participant’s 
personal live were used as an auxiliary variable to measure 
possible support networks. Social support was measured 
using the Oslo 3 Social Support Scale, which is composed 
of three indicators [40]: (i) the number of close confidants 
who can be relied upon in the event of serious problems, 
(ii) the sense of concern that other people show the par-
ticipant and (iii) the ease of gaining practical help from 
neighbours. This allowed to differentiate between ‘low sup-
port’, ‘medium support’ and ‘strong support’.
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migraine also meet the characteristics for migraine with 
aura, as do 42.9% of men. Women are more likely to expe-
rience migraine, but men report symptoms of aura more 
often than women. In addition, migraine is more common 
among younger women and men, and decreases steadily 
with age. Prevalence is highest among women aged 
between 18 and 29 years, and among men aged between 
30 and 39 years (Figure 2).
10.3% of women and 6.5% of men meet all of the diag-
nostic criteria for tension-type headache. Symptoms of 
chronic tension-type headache are reported by 3.4% of 
those affected. Overall, 0.6% report chronic and 8.1% epi-
sodic tension-type headache. Again, if these figures are 
added to those for probable tension-type headache, 28.2% 
of women and 21.8% of men are affected by this condition. 
As is the case with migraine, tension-type headache is more 
common among people of working age and decreases 
steadily with age. Men have a lower prevalence of overall 
headache as well as for the two most common types, 
migraine and tension-type headache, than women. The 
differences identified between women and men remain 
stable within the age groups.
Figure 3 shows the distribution of participants suffering 
at least one headache over the past twelve months by diag-
nostic criteria. The graphs demonstrate that some respond-
ents are affected by both migraine and tension-type 
headache. Overall, 51.1% of participants reported that they 
had had a headache in the past twelve months. Around 
one third of these respondents (35.0%) reported two dif-
ferent types of headache. 14.9% of respondents described 
headache that could not be clearly categorised either as 
a migraine or as a tension-type headache. 75.6% of 
those with 95% confidence intervals (95% CI), are weighted 




A total of 5,009 respondents (unweighted figures) partici-
pated in the study on headache, back and neck pain in 
Germany; 2,634 were women (52.6%) and 2,375 were men 
(47.4%). The distribution of the sample by age, sex and 
education shows that the study participants tended to be 
somewhat older and more educated than the population 
update of the Federal Statistical Office and the microcen-
sus (Annex Table 1).
3.2 Frequency of headache disorders
A total of 57.5% of women and 44.4% of men reported that 
they had at least one headache in the twelve months before 
the survey. 14.8% of women and 6.0% of men were affect-
ed by migraine that met all of the diagnostic criteria. 9.1% 
of those affected by migraine have chronic headache. 1.2% 
of participants have chronic migraine and 9.6% have epi-
sodic migraine. Many other respondents with recurrent 
headache only met three out of the four characteristics and, 
therefore, were classified as having probable migraine. If 
these figures are added to those for definite migraine, the 
proportion of people affected by migraine increases sub-
stantially to 28.4% of women and 18.0% of men. In addi-
tion, these people may also have symptoms of aura. Self-re-
ported data show that 32.1% of women with definite 
14.8% of women and 6.0% 
of men in Germany suffer 
from migraine; additionally, 
13.7% of women and 12.0% 
of men have probable 
migraine.
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months (Figure 4). Men are more likely than women to 
report a mild (30.2%) or moderate (50.6%) headache. This 
tendency also largely applies to respondents with migraine 
or tension-type headache. Women with migraine tend to 
describe their pain as severe (61.3%) or moderate (38.4%). 
This trend is particularly strong among women with chronic 
migraine, of whom, 79.3% describe their headache as severe. 
respondents suffering from headache had either a migraine 
or tension-type headache. Approximately one in ten (9.5%) 
people suffering from headache showed symptoms of both 
migraine and tension-type headache (Figure 3).
Among respondents suffering from headache, women 
are the most likely to report that they have had a moderate 
(54.4%) or severe (27.7%) headache in the past twelve 
Figure 2 
Prevalence of migraine and tension-type 
headache in adults by sex and age 
(n=2,634 women, n=2,375 men) 














50 – < 60  ≥ 70 Total
MenWomen
15 – < 30 30 – < 40 60 – < 7040 – < 50 50 – < 60 ≥ 70 Total
Tension-type headache (probable)
Figure 3 
Distribution of headache in the past twelve 
months by headache type (N=5,009) 
Source: Study on headache, back and neck pain 
in Germany (2019/2020) Proportion (%)





Probable MIG and TTH
Definite TTH and 
 probable MIG
Definite MIG and 
 probable TTH
Definite MIG and TTH
Other headache
Have you had a headache 







MIG = Migraine, TTH = Tension-type headache
10.3% of women and 6.5% of 
men in Germany are affected 
by tension-type headache; 
additionally, 18.0% of  
women and 15.3% of men 
have probable tension-type 
headache.
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headache. On average, men who are affected by migraine 
are affected slightly more often per month than women. 
However, this difference is not significant. The data for the 
twelve-month period show that, on average, headache lasts 
longer for women than men, and this also applies to 
migraine (Table 2). Both women and men with definite ten-
sion-type headache report that their headache lasts less 
than a day. No noteworthy differences with regard to the 
length of the headaches were found between respondents 
with chronic compared to those with episodic headache. 
The proportion of men who have severe attacks is lower at 
54.5%. However, similarly to women, 72.1% of men with 
chronic migraine describe their pain as severe. Respondents 
generally describe the pain associated with tension-type 
headache as moderate (women 72.0%, men 61.7%); in con-
trast to the results for migraine, this also applies to chronic 
tension-type headache.
On average, women are affected by overall headache 
on more days per month than men (Table 2). No signifi-
cant sex-specific differences were found for tension-type 
Figure 4 
Intensity of headache, including (definite) 
migraine and (definite) tension-type headache
Source: Study on headache, back and neck pain 
in Germany (2019/2020)
Proportion (%)
0            10          20           30          40           50          60          70          80           90          100
Headache (in the last twelve months)  Women (n=1,365)
Men (n=984)
Migraine (definite)                                   Women (n=340)
Men (n=113)




Frequency per month and duration for 
headache in general, (definite) migraine and 
(definite) tension-type headache








AM MD STD AM MD STD AM MD STD
Days with a 
headache  
(in days  
per month)
Women 3.2 1.0 5.3 4.0 1.5 6.2 2.6 1.0 4.5
(n=1,321) (n=332) (n=231)
Men 2.4 1.0 4.6 4.4 1.0 6.6 2.2 1.0 4.0
(n=958) (n=111) (n=143)
Duration of the 
headache 
(in days)
Women 1.0 0.1 2.1 1.3 1.0 1.1 0.6 0.1 1.1
(n=1,289) (n=340) (n=235)
Men 0.8 0.1 2.4 0.8 1.0 0.7 0.6 0.1 0.8
(n=936) (n=113) (n=148)
Bold  = A significant difference in the mean between women and men (p-value <0.05) 
AM = mean, MD = median, STD = standard deviation
Women from all age groups 
are more likely to experience 
migraine and tension-type 
headache than men.
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Respondents with migraine and tension-type headache 
often report severe back pain (migraine 30.0%, tension-type 
headache 23.7%) or neck pain (migraine 31.4%, ten-
sion-type headache 19.2%) (Table 3). This is most evident 
when the results are compared with those for people with-
out headache: only 12.6% of people without headache 
report severe back pain and only 6.7% describe severe neck 
pain. A high proportion of people with migraine also dis-
played depressive symptoms (24.9%) or an anxiety disor-
der (20.5%). In comparison, 15.3% of those without 
headache reported depressive symptoms and 8.7% showed 
symptoms of an anxiety disorder. Very few sex-specific dif-
ferences were identified for the comorbidities considered 
in this study. Participants with chronic migraine reported 
severe neck pain (62.5%) and depressive symptoms 
(71.6%) particularly often. In contrast, chronic tension-type 
headache is not associated with a higher frequency of 
any of the comorbidities under consideration.
An association was found for both women and men 
between the intensity and frequency of headache in the past 
twelve months, with intensity increasing with the frequency 
of headache attacks (Figure 5). 24.0% of women who have 
headache on less than three days a month describe them as 
severe, 55.7 % of women who have headache on more than 
fifteen days a month describe them as severe. A similar pic-
ture emerges among men: when they have a headache on 
less than three days a month, 14.4% describe them as severe, 
whereas, among those who have headaches on more than 
fifteen days a month, 67.6% describe them as severe.
3.3 Comorbidities associated with headache
As headache may be accompanied by certain physical 
illnesses and by higher levels of mental stress [13], this 
study examined the links between selected conditions and 
migraine and tension-type headache. Table 3 shows the 
proportion of participants with comorbidities within the 
groups of people with migraine, tension-type headache or 
without headache. The respondents without any headache 
during the last twelve months were used as the compari-
son group (sigificancy test). 
Figure 5 
Intensity of headache over the past twelve 
months by frequency of attack per month 
(n=1,320 women, n=957 men)
Source: Study on headache, back and neck pain 
in Germany (2019/2020)
Proportion (%)
0                  20                40                   60                 80                100
Low Medium Severe
0                  20                40                   60                 80                100
MenWomen 
Up to 3 days
4 to under 8 days
9 to under 14 days
  More than 15 days
Migraines, in particular, are 
accompanied by a higher 
frequency of depressive 
symptoms and anxiety  
disorders.
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92.8% of women and 75.5% of men take medication to treat 
acute pain. The proportions of women and men who take 
medication for chronic tension-type headache are lower 
than those who do so for episodic headache (women 73.4%, 
men 37.3% vs. women 93.9%, men 74.9%). A significantly 
lower proportion of people uses medication to prevent 
headache or other pain: 3.2% of all respondents with any 
headache in the last twelve months, 4.7% of those with 
migraine (chronic migraine 9.8%) and 1.6% of people with 
tension-type headache (chronic tension-type headache 
4.2%) used medication as a prophylaxis. Only slight differ-
ences by sex were found. 
Women not only take medication to treat acute headaches 
and other pain more frequently than men, but also do so 
more regularly. Among all respondents who reported any 
headache in the last twelve months, women take medica-
tion on 4.4 days a month on average, with men doing so 
on 2.8 days a month. In contrast, no significant differences 
were identified between women and men for (definite) 
migraine or (definite) tension-type headache. On average, 
respondents with migraine use medication to treat acute 
headaches and other pain on 5.8 days a month; participants 
with tension-type headache do so on 3.0 days a month. On 
average, medication is used to treat acute pain associated 
with chronic migraine on 14.7 days a month, and on 9.9 
days a month for chronic tension-type headache. The most 
3.4 Outpatient medical treatment and the use of  
medication
Among participants who reported any headache in the 
twelve months before the survey, 22.0% of women and 
17.1% of men stated that they had consulted a doctor about 
their condition. The results are similar for participants with 
tension-type headache: 22.1% of women and 17.0% of men 
consulted a doctor in the twelve months before the survey 
about their condition. However, people with migraine 
reported a higher rate of medical treatment: 40.6% of wom-
en affected by migraine and 38.5% of men with migraine 
sought medical treatment for their headache in the twelve 
months before the survey. Moreover, women and men who 
reported chronic migraine have received treatment signif-
icantly more often with 59.2% and 79.6%, respectively. This 
also applies to people with chronic tension-type headache 
(women 71.8%, men 24.0%).
Of all participants who reported any headache in the 
last twelve months, 82.5% of women and 67.0% of men 
stated that they take medication to treat acute pain. Among 
those with (definite) migraine, the numbers are significantly 
higher at 90.9% of women and 83.1% of men. Almost all 
respondents with chronic migraine take medication to treat 
acute headaches and other pain (women 97.0%, men 
96.3%). Among those with (definite) tension-type headache, 
Back pain Neck pain Depressive symptoms Anxiety disorder
Migraine (definite) (n=449) 30,0 % 31,4 % 24,9 % 20,5 %
Tension-type headache (definite) (n=383) 23,7 % 19,2 % 12,6 % 10,2 %
No headache1 (n=2,632) 12,6 % 6,7 % 15,3 % 8,7 %
1 People answered ‘No’ to the question ‘Have you had a headache in the past twelve months?’
Bold = Significant difference (p-value <0.05) compared with participants without headache; comparison based on the Pearson χ2 test
 Table 3 
The most common comorbidities
Source: Study on headache, back and neck pain 
in Germany (2019/2020)
Tension-type headache and 
migraines occur most 
frequently among people of 
working age and decrease 
steadily with age.
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take a higher than recommended dosage of medication for 
episodic headache. 
3.5 Social determinants of headache
Multivariate analyses were carried out to investigate the 
possible social determinants of migraine and tension-type 
headache (definite: Table 5; probable and other headache 
types: results on request).
The results of the multivariate analyses demonstrate that 
women are almost 4.7 times more likely to have a definite 
migraine than men (Table 5). Women also are almost 2.7 
more likely of having tension-type headache than men. With 
regard to age, the results for both conditions essentially 
confirm the findings from the descriptive analyses: the like-
lihood of having a migraine and tension-type headache 
steadily decreases with age (Table 5). No statistically sig-
nificant associations between migraine or tension-type 
headache and education, unemployment or partnership 
were found. However, an association was found between 
commonly used drugs are ibuprofen, paracetamol and 
acetylsalicylic acid (Table 4). Triptans, which are only used 
to treat migraine, play a greater role among people with 
(definite) migraine compared to all respondents with 
headache. Therefore, triptans are particularly taken by 
people with migraine and are ranked at place four with 
7.3%. Since approximately one in ten people with headache 
showed symptoms of both migraine and tension-type 
headache, some respondents with definite tension-type 
headache also take triptans. Finally, no significant sex- 
specific differences were identified by type of medication.
It appears that in a small group of participants with 
chronic headache these headaches only occur or are exac-
erbated when medication overuse is also present. Specific 
therapeutic approaches, including the withdrawal of pain 
medication, may be indicated in these cases. Signs of 
headache caused by medication overuse are identifiable 
among 1.9% of people with migraine and 0.9% of people 
with tension-type headache. The prevalence among all 
adults is 0.9%. Furthermore, an additional 2.0% appear to 
Table 4 
Use of medication to treat headache 
(percentage of all responses, 
multiple answers possible)1














Ibuprofen 49.7% Ibuprofen 46.2% Ibuprofen 47.8%
Paracetamol 18.7% Paracetamol 17.1% Paracetamol 22.5%
Acetylsalicylic acid 15.0% Acetylsalicylic acid 10.2% Acetylsalicylic acid 14.9%
Metamizole sodium 3.1% Triptan 7.3% Diclofenac 2.6%
Novaminesulfone 2.9% Metamizole sodium 5.4% Triptan 2.4%
Triptan 2.8% Novaminesulfone 4.0% Novaminesulfone 2.1%
Diclofenac 2.3% Diclofenac 2.4% Metamizole sodium 1.9%
Naproxen 0.9% Naproxen 1.2% Celecoxib 1.0%
Mentions 2,320 Mentions 578 Mentions 423
Respondents 2,349 Respondents 453 Respondents 383
1  This table only provides the figures for the eight most commonly mentioned drugs. The figures shown are unweighted.
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case, 14.8% of women and 6.0% of men were affected by 
definite migraine and 10.3% of women and 6.5% of men 
were affected by definite tension-type headache. The fre-
quency of migraine and tension-type headache decreases 
significantly with age. Among all respondents with headache, 
women report mild headache less often and moderate or 
severe headache more often than men. The largest group 
of respondents who reported severe pain is women with 
migraine. Moreover, migraine is particularly frequently 
associated with comorbidities such as back or neck pain, 
depressive symptoms and anxiety disorders. In Germany, 
definite migraine and social support: respondents with a 
high level of social support are less likely of suffering from 
migraine than respondents with a medium level of social 
support.
4. Discussion
57.5% of women and 44.4% of men in Germany report hav-
ing had a headache at least once within the last year. How-
ever, the figures are lower when the clinical criteria for 
migraine and tension-type headache are applied. In this 
Table 5 
 Multinomial regression of the social 
determinants of (definite) migraine and 
(definite) tension-type headache 
(n=2,526 women, n=2,280 men)1
Source: Study on headache, back and neck pain 
in Germany (2019/2020)
Migraine (definite) Tension-type headache (definite)
OR2 p-value (95% CI) OR2 p-value (95% CI)
Sex (Reference group: men)
Women 4.68 <0.001 (3.22–6.80) 2.65 <0.001 (1.85–3.80)
Age group (Reference group: 18–<30 years)
30–<40 years 0.79 n.s. (0.43–1.47) 1.65 n.s. (0.84–3.25)
40–<50 years 0.45 <0.01 (0.26–0.80) 0.69 n.s. (0.34–1.38)
50–<60 years 0.22 <0.001 (0.13–0.39) 0.37 <0.01 (0.20–0.66)
60–<70 years 0.07 <0.001 (0.03–0.13) 0.20 <0.001 (0.11–0.39)
≥70 years 0.02 <0.001 (0.01–0.04) 0.07 <0.001 (0.03–0.16)
Education (Reference group: medium)
Low 0.49 n.s. (0.25–0.99) 0.57 n.s. (0.27–1.20)
High 0.95 n.s. (0.70–1.29) 0.75 n.s. (0.54–1.02)
Unemployment 
(Reference group: employed/retired)
2.11 n.s. (0.76–5.83) 0.81 n.s. (0.24–2.74)
Partnership  
(Reference group: no partnership)
1.05 n.s. (0.73–1.52) 0.94 n.s. (0.63–1.39)
Social support (Reference group: medium)
Low 1.24 n.s. (0.76–2.02) 1.03 n.s. (0.55–1.92)
High 0.63 <0.05 (0.44–0.91) 0.77 n.s. (0.54–1.12)
OR = odds ratio, 95% CI = 95% confidence interval, bold = significant (p <0.05), n.s. = not significant
1  All participants who answered ‘No’ to the initial question ‘Have you had a headache in the past twelve months?’ were used as the reference group in the  
multinomial logistic regression.
2  In multinominal logistic regression relative risk ratios (RRR) are computed to express the strength of ststistical associations. Usually, these are interpreted as 
odds ratios.     
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There is only a small number of population-wide stud-
ies on headache disorders in Germany that have imple-
mented the diagnostic criteria. Moreover, some of the stud-
ies that do so only cover specific regions [24] or certain age 
groups [3, 6, 25, 26, 27]. This limits their comparability with 
the results set out here. However, the headache study con-
ducted by the German Migraine and Headache Society 
(DMKG study) combines the data from the Study of Health 
in Pomerania (SHIP), the Cooperative Health Research in 
the Augsburg Region (KORA) study and the Dortmund 
Health Study (DOGS) [5]. Nevertheless, it is important to 
note that each of these studies collected headache data 
differently. The DMKG study found that definite migraine 
affects 10.0% of women and 2.2% of men. Definite ten-
sion-type headache was identified among 19.7% of women 
and 17.2% of men. As such, the present study recorded a 
higher prevalence of migraine and a lower prevalence of 
tension-type headaches than the DMKG study. However, if 
the studies on which the DMKG overview report is based 
are considered separately, the prevalence estimated by the 
present study are actually similar for migraine compared 
to the DOGS and KORA studies, and consistently lower for 
tension-type headache [5]. 
The German Headache Consortium (GHC) Study, which 
provides results for specific regions in Germany (Essen, 
Münster and Sigmaringen), found that 19.1% of women 
and 7.1% of men suffer from (definite) migraine [6]. These 
values are slightly higher than the results presented in this 
study. The GHC study found that 3.8% of women and 3.4% 
of men are affected by (definite) tension-type headache. 
The results presented here are higher, at 10.3% for women 
and 6.5% for men. Both studies, the DMKG and GHC, 
people with headache receive a low level of treatment, with 
22.0% of women and 17.1% of men consulting a doctor 
within a year about their condition. People with migraine 
have a higher rate of treatment. Finally, 82.5% of women 
and 67.0% of men suffering from headache use medica-
tion to treat acute pain. The most common drugs taken 
are ibuprofen, paracetamol and acetylsalicylic acid.
When comparing these results to other findings, it is 
important to take into account the methodological differ-
ences in how studies identify migraine (or tension-type 
headache). Variation between studies can be explained by 
questionnaire design, the implementation of the diagnos-
tic criteria using a wording understandable by non-spe-
cialist people, survey type, survey period and the approach 
taken in cases where an individual is affected by various 
types of headache [1]. The current study reports a smaller 
proportion of people who have had headache in the past 
twelve months compared to a telephone survey under-
taken in 2004. The 2004 survey, which was also carried 
out by the RKI, found that 66.6% of women and 53.0% of 
men reported any headache in the last twelve months com-
pared with 57.5% of women and 44.4% of men in the pres-
ent survey [2]. The 2004 study also identified a somewhat 
higher proportion of respondents with (definite) migraine: 
15.6% of women and 5.3% of men [2]. However, in addi-
tion to slight variations in how the two studies define 
migraine, the differences in prevalence could also be due 
to differences in the questionnaires (such as the order in 
which the questions were asked, or how the diagnostic 
criteria were integrated into the study). A study that com-
pared headache prevalence in Germany between the 1990s 
and 2009 found little evidence of temporal trends [48].
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presented here also describe important comorbidities 
related to migraine and tension-type headache: depres-
sive symptoms, anxiety disorders and back and neck pain 
are the most important comorbidities. However, it must 
be noted that this is not an exhaustive list. There are many 
other notable comorbidities, such as fibromyalgia and 
sleep disorders, that may also show similarly strong asso-
ciations with headache disorders.
An earlier population-wide survey of Germany esti-
mated the use of medical care to be 41.6%, which is 
slightly higher than in the present study [2]. The present 
study found that 40.0% of people with migraine and 
20.2% of people with tension-type headache coordinate 
their treatment with a doctor. Another population-wide 
study from 2016 found that almost one in two people with 
headache consult a doctor [50]. The overall rather low 
level of care and scarce attempts to seek help by people 
affected by headache disorders may be explained through 
their use of self-medication. It can therefore be assumed 
that most people with migraine and tension-type headache 
who use medication-based prophylaxis do not follow med-
ical guidelines. The rare use of triptans to treat acute pain 
further suggests that these patients do not necessarily 
follow the recommendations set out by professional med-
ical associations. As such, it would be important to dis-
cuss the ways in which impartial medical advice can be 
improved to encourage people with headache disorders 
to make informed decisions and to follow guideline-based 
care. 
The risks associated with not seeking medical help and 
with self-medication include the development of chronic 
pain, and medication overuse [9–11]. Medication overuse 
differentiate between definite and probable migraine. How-
ever, the identified prevalence is drawn from different recall 
periods (six months in the case of the DMKG, and twelve 
months in the case of the GHC),the two studies refer to 
different regions and vary in the methods used to record 
migraine and tension-type headache [1]. In contrast, a pop-
ulation-wide survey from 2016 found that 7.2% of the pop-
ulation is affected by migraine and 12.4% by tension-type 
headache [27]. However, these results refer to the last six 
months and – as was the case with the DMKG study – the 
diagnostic criteria were not implemented. Instead, the par-
ticipants were asked whether they had ever been medically 
diagnosed as having a headache (including migraine and 
tension-type headache).
 Other findings presented here are comparable with 
the results of other studies. Other studies have provided 
similar estimates of the number of days that people are 
affected by headache per month. In a study conducted in 
the 1990s, participants with migraine described having a 
headache on 2.8 days per month, whereas those with ten-
sion-type headache reported headache on 2.9 days per 
month [49]. The DMKG study found that people with 
migraine have headache on average for four days a month 
[36]. Similarly, the present study estimated a mean of 4.1 
days per month for migraine and 2.4 days per month for 
tension-type headache. A larger study of people with 
migraine in the United States also found a similar aver-
age duration of attack of around one day [22]. In addition, 
whereas the US study found that almost two-thirds of 
participants with migraine described the pain intensity as 
severe [49], in the present study, 59.4% of respondents 
with migraine described their pain as severe. The results 
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respondents to classify the type of pain that they experi-
ence. Nevertheless, it is impossible to rule out the risk 
that individual indicators such as migraine with aura or 
headache caused by medication overuse may either be 
over or underestimated. The same applies to chronicity, 
which this survey was unable to fully account for. How-
ever, the smooth implementation of the study in the field, 
the small number of missing values and the plausibility 
of its findings suggest that the respondents certainly 
understood the questionnaire.
As limitation can be noted that the study is affected by 
decreasing willingness of general participation in surveys. 
The study is also based on the assumption that everyone 
over the age of 18 years can be reached equally by tele-
phone and that all possible landline connections and 
mobile phone numbers were included in the overall sam-
ple. The response rate was calculated using the American 
Association for Public Opinion Research’s criteria for 
‘response rate 3’. In some cases, calculations that use 
other criteria may produce significantly higher response 
rates. However, the response rate reported here is com-
parable to that of studies conducted by the RKI and oth-
ers [52]. Since the sample was adjusted to correct for spe-
cific characteristics, the data quality can be regarded as 
high. Nevertheless, it is unclear whether, for example, 
people suffering from chronic illness are adequately rep-
resented in the study and, if not, what impact this could 
have on the prevalence of headache disorders. Further-
more, estimates that are based on a small proportion of 
respondents, such as people with medication overuse or 
highly frequent headache attacks, are subject to a degree 
of uncertainty. 
can itself be associated with headache. The prevalence of 
medication overuse headache is estimated to be up to 2% 
[37, 51]; the DOGS, KORA and SHIP studies estimated the 
prevalence to be around 1% [36]. The current study found 
a prevalence of around 1% for people with headache dis-
orders. It can be assumed that the frequency of medication 
overuse headache strongly depends on the type of survey 
and other study characteristics, which means that it is very 
difficult to provide a precise estimate of the prevalence of 
this type of headache.
The results presented here provide up-to-date and reli-
able information about the overall incidence of headache 
disorders in Germany. The sample design on which the 
results are based, the large number of participants (over 
5,000) and the weighting used, ensure a high degree of 
representativeness. By translating the diagnostic criteria 
of the ICHD into language that is easy to understand, 
headache disorders such as migraine and tension-type 
headache can be distinguished from other types of headache. 
Furthermore, this study has demonstrated the feasibility 
of identifying different headache types even if the same 
respondent is affected by more than one form of the dis-
order. As the respondents don’t need to decide for one 
of the headache for which to report, a possible under-
reporting is not expected. However, integrating diagnos-
tic criteria into studies can be challenging as the criteria 
can be translated in different ways, and respondents still 
need to provide information, for example, about the fre-
quency of headache attacks that occurred over different 
study periods (their lifetime, a period of twelve months). 
However, recurring headache has a great impact on 
people’s lives, and it should therefore be possible for 
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significantly from these figures [17, 19]. As such, different 
results can also be expected for Germany. In addition, the 
BURDEN 2020 study also provides estimates for Germany 
at the regional level. Claims data and older study data 
provide evidence of regional variation that should be further 
analysed [1, 2, 5]. Due to rather small case numbers in 
population based studies regional estimates can often only 
be made using small area estimation techniques. The RKI 
has already carried out preliminary work on this subject, 
which will be further developed using the example of migraine 
and tension-type headache for the purposes of disease 
burden calculations within the BURDEN 2020 study [53].
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4.1 Outlook
Headache disorders are often very stressful and have a 
severe impact on the quality of life of the people who are 
affected and those around them. Since relatively few peo-
ple with headache disorders seek medical treatment or 
receive wage replacement benefits, headache disorders are 
not particularly evident in claims data. However, studies 
that focus on the burden of disease and that quantify the 
loss of healthy lifetime due to illness in a population clear-
ly demonstrate the public-health relevance of headache 
disorders.
The BURDEN 2020 study uses a population survey to 
quantify the prevalence and severity distribution of pain 
disorders as part of a national study of the burden of dis-
ease. This procedure has been proven to be effective in the 
case of migraine and tension-type headache. In order to 
measure prevalence, the criteria set out in the ICHD were 
used to define migraine and tension-type headache. This 
study was able to properly implement the approach used 
by the Global Burden of Disease Study. There is very little 
difference between the prevalence identified by the Global 
Burden of Disease Study [20] and the present study. The 
main difference between the study results is the lower 
preva lence of tension-type headache, which diminishes the 
burden associated with this condition in the national 
study’s calculations of YLD. 
This article has not taken the next step of estimating 
severity distributions for migraine or tension-type headache. 
The Global Burden of Disease Study provides global (coun-
try-unspecific) estimates of severity distribution. In the 
case of many diseases, country-specific estimates deviate 
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Annex Table 1 
The sociodemographic characteristics 
of the study population compared 
with official statistics
Source: Study on headache, back and neck pain 
in Germany (2019/2020), 
Destatis population update*





18–29 years 9,2% 16,6%
30–39 years 11,4% 15,3%
40–49 years 13,8% 15,0%
50–59 years 21,6% 19,4%
60–69 years 21,7% 14,8%
≥70 years 22,4% 18,8%
Education
Low 5,0% 17,5%
Medium (no Abitur) 29,7% 41,9%
Medium (has Abitur) 13,0% 15,4%
High 52,4% 25,2%
*  Official statistics based on the population update (as of 31 December 2018) 
and the results of the 2017 microcensus.
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